Connect with us

Technology

BioWorld by Clarivate Celebrates Nine Wins at 2024 APEX Awards

Published

on

Recognized for excellence in writing, news, mental health, financial/investment and economics categories

LONDON, July 18, 2024 /PRNewswire/ — BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has been honored with nine 2024 APEX Awards for Publication Excellence. This achievement underscores the BioWorld mission to deliver superior journalistic excellence, data-driven analysis and cutting-edge digital publishing.

The APEX Awards, now in their 36th year, recognize outstanding work by professional communicators in areas such as graphic design, editorial content, and overall communications excellence. With over 1,100 entries this year, the competition was fierce, making these nine wins a testament to the continued leadership and innovation in the field by BioWorld.

Lynn Yoffee, Publisher, BioWorld, said: “This recognition from the APEX Awards is a testament to our team’s unwavering dedication to journalistic excellence. In a fast-paced and ever-changing industry, BioWorld remains a leader through our insightful analysis and compelling storytelling, providing crucial insights into the development of therapeutics and devices, the companies driving these innovations, the business deals shaping the market, and the regulatory challenges that safeguard the process. We are proud to be at the forefront of delivering critical information that drives innovation and improves lives worldwide.”

Henry Levy, President, Life Science and Healthcare, Clarivate, said: “The BioWorld suite of news services delivers actionable intelligence on the most innovative therapeutics and medical technologies in development. They also make all of our products across Cortellis and our RWD solutions stronger by aligning to the key occurrences in the market.  The accolades received from the APEX Awards reflect the ongoing dedication of the BioWorld team to producing award-winning journalism that resonates with readers and the publishing industry alike.”

APEX Grand Awards honor outstanding works in each main category and Awards of Excellence recognize exceptional entries in the sub-categories. BioWorld has been recognized in the following 2024 APEX Awards categories:

Grand Award – Writing Category:
Annette Boyle, BioWorld MedTech
Cytovale gets FDA nod for 10-minute sepsis test
Cytovale Inc. received U.S. FDA 510(k) clearance for its Intellisep sepsis test, which can aid in the diagnosis of the often-fatal condition within 10 minutes. Cytovale is one of several companies and collaborations that aim to sharply reduce the time to diagnosis and the mortality rate for sepsis by providing quicker, more informative test results and standardizing protocols.

Grand Award – Writing Category:
Nuala Moran, BioWorld MedTech, BioWorld, and BioWorld Science
Let there be walk: Onward Medical sees first use of movement-restoring lead
The researchers who enabled patients with spinal cord injuries to walk independently after implanting programmable electrodes below their lesions have now taken things one step further, restoring direct communication from the brain to the spinal cord, enabling the brain rather than an external computer to direct leg movements.

Award for Publication Excellence – Writing the Entire Issue Category:
Jennifer Boggs, Karen Carey, Anette Breindl, Mari Serebrov, Marian Chu, Vinod Kamalakannan, Lee Landenberger, Harini Mathavan, Randy Osborne, Caroline Richards, Tamra Sami, Ann Marie Griffith, Amanda Lanier
BioWorld – June 6, 2023
This issue exemplifies the typical content delivered every business day, featuring nine stories and a podcast covering global industry news. Highlights include a series A financing for a gene therapy company, phase III data from the American Society of Clinical Oncology conference, an M&A that took a public company private, and a comprehensive infographic on R&D spending.

Award for Publication Excellence in Design & Illustration – Infographics Category:
Ann Marie Griffith and Amanda Lanier, BioWorld 
Top trends in 2023’s post-pandemic economy
This infographic provides a visual illustration of the impact that financial investment, licensing deals and M&As have on the biopharma industry’s ability to advance innovation. It gives a historical perspective of how 2023 fits into the bigger picture and includes expert commentary and graphics packed with data, assessing the biopharma industry’s overall health.

Awards for Publication Excellence in Writing – Series Category:
Tamra Sami and Mari Serebrov, BioWorld, Anette Breindl, BioWorld Science
Radiopharmaceuticals: The next big disrupter?
Radiopharmaceuticals have been used for a long time for diagnostics, but radiopharma therapies are entering a new era in which they are becoming widely accepted as a key tool in the oncology armamentarium potentially providing patients with a big bump in efficacy with fewer side effects and less damage to healthy tissue. In this eight-part series, BioWorld takes a deep dive into this new treatment modality to explore what the new uses or alternatives are and what the future of radiopharmaceutical therapy might look like.

Awards for Publication Excellence in Writing – News Category:
Karen Carey, BioWorld 
Wegovy wows investors, sends ripples throughout GLP-1 developer space
Investors have known for some time that the GLP-1 receptor agonist class offers tremendous promise for treating the underserved obesity population worldwide, but news from Novo Nordisk A/S on cardiovascular outcomes data sent a shiver throughout the space.

Awards for Publication Excellence in Writing – Mental Health Category:
Anette Breindl, BioWorld Science
ECNP 2023: Boosting fear unlearning is one avenue toward treating PTSD
For most psychiatric illnesses, the precipitating event is mysterious. Many conditions are thought to result from a mix of genetic risk and environmental factors, but the specific trigger remains unknown. In post-traumatic stress disorder (PTSD), the environmental trigger is usually clear. In many cases, it is all the affected individuals can think about. “Intrusive reliving” of the triggering situation is one of the core features of PTSD.

Awards for Publication Excellence in Writing – Financial and Investment Category:
Amanda Lanier, BioWorld
Larger value, fewer transactions: biopharma deals up modestly while M&As soar 80% in 2023
The landscape of biopharma deals and M&As has seen a transformative shift, with a year-over-year drop in transaction numbers while value has increased. Overall, biopharma deals saw an uptick in value of nearly 6%, and biopharma M&As concurrently soared 80% higher in value than the previous year.

Awards for Publication Excellence in Writing – Economics/The Economy Category:
Marian (YoonJee) Chu and Tamra Sami, BioWorld
Asia biotech ecosystems roaring back in 2023
If the COVID-19 pandemic shocked countries to build self-reliance in biomedical ecosystems, the re-opening of borders in 2023 kickstarted international collaborations to grow major biohubs in Asia. Countries in the Asia Pacific region – including Singapore, China, Japan, Korea and Australia – increasingly drew overseas investors and collaborators, helping each country grow national biotech capabilities and expertise.

Join the conversation and mention BioWorld on X at BioWorld, BioWorldMedTech and BioWorldScience or on LinkedIn  at BioWorld, BioWorld MedTech and BioWorld News. Connect with Clarivate for Life Sciences & Healthcare on X and LinkedIn

About BioWorld
With writers and editors stationed around the globe, BioWorld published by Clarivate, reports the breaking news – and provides key perspective on hundreds of therapeutics and devices in development, the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes. BioWorld has a long tradition of excellence in journalism. Collectively, the news services have been honored with 61 awards dating back to 1998.

About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com.

Media Contact: 
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
newsroom@clarivate.com

Logo – https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/bioworld-by-clarivate-celebrates-nine-wins-at-2024-apex-awards-302200201.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

ChipMOS EXPECTS 6.3% FULL YEAR 2024 REVENUE GROWTH, WITH A 5.4% YoY DECEMBER 2024 REVENUE DECLINE AND A 5.7% YoY 4Q24 REVENUE DECLINE

Published

on

By

HSINCHU, Jan. 10, 2025 /PRNewswire-FirstCall/ — ChipMOS TECHNOLOGIES INC. (“ChipMOS” or the “Company”) (Taiwan Stock Exchange: 8150 and Nasdaq: IMOS), an industry leading provider of outsourced semiconductor assembly and test services (“OSAT”), today reported its unaudited consolidated revenue for the month of December 2024 and for the fourth quarter ended December 31, 2024. All U.S. dollar figures cited in this press release are based on the exchange rate of NT$32.79 to US$1.00 as of December 31, 2024. This would represent full year 2024 revenue growth of approximately 6.3% compared to the full year 2023.

Revenue for the fourth quarter of 2024 was NT$5,399.6 million or US$164.7 million, representing a decrease of 5.7% from the fourth quarter of 2023, and a decrease of 11.0% from the third quarter of 2024. The Company noted that while the quarterly decline reflects macro industry pricing and demand headwinds, the strong full year 2024 revenue growth reflects continued leadership in its core markets.

Revenue for the month of December 2024 was NT$1,780.1 million or US$54.3 million, representing a decrease of 3.0% from November 2024, and a decrease of 5.4% from December 2023.

Consolidated Monthly Revenues (Unaudited)

December 2024

November 2024

December 2023

MoM Change

YoY Change

Revenues

   (NT$ million)

1,780.1

1,834.6

1,881.5

-3.0 %

-5.4 %

Revenues

   (US$ million)

54.3

55.9

57.4

-3.0 %

-5.4 %

 

Consolidated Quarterly Revenues (Unaudited)

Fourth Quarter

2024

Third Quarter

2024

Fourth Quarter

2023

QoQ Change

YoY Change

Revenues

   (NT$ million)

5,399.6

6,068.0

5,725.4

-11.0 %

-5.7 %

Revenues

   (US$ million)

164.7

185.1

174.6

-11.0 %

-5.7 %

About ChipMOS TECHNOLOGIES INC.:

ChipMOS TECHNOLOGIES INC. (“ChipMOS” or the “Company”) (Taiwan Stock Exchange: 8150 and Nasdaq: IMOS) (www.chipmos.com) is an industry leading provider of outsourced semiconductor assembly and test services. With advanced facilities in Hsinchu Science Park, Hsinchu Industrial Park and Southern Taiwan Science Park in Taiwan, ChipMOS is known for its track record of excellence and history of innovation. The Company provides end-to-end assembly and test services to leading fabless semiconductor companies, integrated device manufacturers and independent semiconductor foundries serving virtually all end markets worldwide. 

Forward-Looking Statements:

This press release may contain certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘projects,’ ‘intends,’ ‘should,’ ‘seeks,’ ‘estimates,’ ‘future’ or similar expressions or by discussion of, among other things, strategies, goals, plans or intentions. These statements may include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Actual results may differ materially in the future from those reflected in forward-looking statements contained in this document, due to various factors. Further information regarding these risks, uncertainties and other factors are included in the Company’s most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) and in the Company’s other filings with the SEC.

Contacts:

In Taiwan

Jesse Huang

ChipMOS TECHNOLOGIES INC.

+886-6-5052388 ext. 7715

IR@chipmos.com

In the U.S.

David Pasquale

Global IR Partners

+1-914-337-8801

dpasquale@globalirpartners.com 

View original content:https://www.prnewswire.com/news-releases/chipmos-expects-6-3-full-year-2024-revenue-growth-with-a-5-4-yoy-december-2024-revenue-decline-and-a-5-7-yoy-4q24-revenue-decline-302347705.html

SOURCE ChipMOS TECHNOLOGIES INC.

Continue Reading

Technology

16 Press Releases You Need to See This Week

Published

on

By

Plus, press release highlights from CES 2025.

NEW YORK, Jan. 10, 2025 /PRNewswire/ — With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week’s most newsworthy and popular releases, here’s a recap of some major stories from the week that shouldn’t be missed.

The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download.

McDonald’s New McValue Platform Is Finally Here
Fans can mix and match with the new Buy One, Add One for $1 offer and fuel up for less with the popular $5 Meal Deal. The brand marks the moment by partnering with John Cena and gifting fans millions of dollars in entertainment, lifestyle promos.ADP National Employment Report: Private Sector Employment Increased by 122,000 Jobs in December; Annual Pay was Up 4.6%
“The labor market downshifted to a more modest pace of growth in the final month of 2024, with a slowdown in both hiring and pay gains,” said Nela Richardson, chief economist, ADP. “Health care stood out in the second half of the year, creating more jobs than any other sector.”Big Lots Closes Sale to Gordon Brothers Retail Partners
Bruce Thorn, Big Lots’ President and Chief Executive Officer, said, “We are pleased to close this strategic transaction, which provides a framework to preserve thousands of jobs, maximize value, and maintain the Big Lots brand.”Globally Renowned Investor and Entrepreneur Kevin O’Leary Joining The People’s Bid for TikTok
The bid aims to purchase TikTok’s U.S. assets and rebuild the platform in a way that prioritizes the privacy of its 170 million American users.NASA to Explore Two Landing Options for Returning Samples from Mars
“Pursuing two potential paths forward will ensure that NASA is able bring these samples back from Mars with significant cost and schedule saving compared to the previous plan,” said NASA Administrator Bill Nelson. “These samples have the potential to change the way we understand Mars, our universe, and – ultimately – ourselves.”Tripadvisor Reveals 2025’s Must-Visit Destinations: Top Picks From Travelers Around the World This year Tripadvisor introduces two new subcategories; Solo Travel Destinations and a special sub-category in celebration of Tripadvisor’s 25th anniversary honoring the Top Destinations of the Last 25 Years based on all time reviews.Ulta Beauty Teams Up with Instacart to Deliver Beauty in a Flash Nationwide
Beauty meets convenience with the largest specialty U.S. beauty retailer now available on Instacart for delivery in as fast as an hour from more than 1,400 stores.Nation’s Top 300 Teen Scientists Selected for Achievements in STEM Innovation and Leadership in Nation’s Oldest and Most Prestigious High School Competition
The 300 scholars will be awarded $2,000 each and their schools will be awarded $2,000 for each enrolled scholar. Scholars were chosen based on their outstanding research, leadership skills, community involvement, commitment to academics, creativity in asking scientific questions and exceptional promise as STEM leaders.$5 Bowls with Five Choices: KFC® Debuts Hot New Lineup of Flavorful Bowls, Including Anticipated Return of Nashville Hot Sauce
Indulge your cravings with a hearty, warm, comforting bowl this winter for just $5 each, making your post-holiday wallet happy. Paramount and Comcast Announce Multi-Year Distribution Agreements
The multi-year deals feature ongoing carriage of Paramount’s networks, including CBS, BET, Comedy Central, MTV, Nickelodeon, Paramount Network and more. Comcast subscribers will also retain access to Paramount’s popular streaming services across Paramount+, Pluto TV and BET+.Michael J. Fox Honored with Presidential Medal of Freedom
President Biden presented Fox with the medal, which honors individuals who have made exemplary contributions to the prosperity, values, or security of the United States, world peace, or other significant societal, public or private endeavors.Hyundai Vehicles Available to “Add to Cart” on Amazon Autos
Car buyers around the U.S. can browse, order and finance any new Hyundai vehicle through a participating Hyundai dealer directly on Amazon Autos, and schedule a pickup from the dealer.The Latest Innovation from CHIPS AHOY! Is…Not A Cookie?! Introducing New CHIPS AHOY! Baked Bites – Bite-Sized Blondies to Satisfy Your Sweet Tooth
Baked into a square shape with a soft and chewy texture inspired by a brownie, CHIPS AHOY! Baked Bites, Blondie variety, are made with delicious, real chocolate chips and no high fructose corn syrup, offering an entirely reimagined CHIPS AHOY! experience. Buffalo thunders back as Zillow’s hottest market for 2025
“Shoppers nationwide should see more options for sale than in recent years, along with slow and steady price growth. That’s the good news. But both buyers and sellers should expect unpredictable mortgage rates,” said Skylar Olsen, Zillow chief economist.Girl Scouts’ 2025 Cookie Season Kicks Off Nationally, Helping Girls Across the Country Unbox Brighter Futures for Themselves
At the close of the 2025 cookie season, two beloved cookie flavors, Girl Scout S’mores® and Toast-Yay!®, will be retired.United Announces Accelerated Timeline for Starlink’s Industry-Leading Connectivity in the Sky
The airline now expects to begin testing Starlink next month with the first commercial flight anticipated to take off this spring on a United Embraer E-175 aircraft. Ultimately, United will add Starlink to its entire fleet.

Read more of the latest releases from PR Newswire.

Do you have a press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most.

CES 2025

CES took over Las Vegas — and the wire — this week as companies from a range of industries shared news of their latest consumer technology innovations. From advances in mobility and AI to medtech, smart homes and much more, PR Newswire is here to help journalists and consumers keep track of the announcements tied to the consumer electronics tradeshow.

Here are just a few of the big CES press releases sent this week:

What Not to Miss at CES 2025XREAL Announces Groundbreaking Collaborations at CES 2025EcoFlow Debuts AI-Powered OASIS at CES 2025, Maximizing Energy Savings and Extreme Weather PrepSony Exhibits at CES® 2025Exclusive to CES 2025: Bird Buddy Goes Beyond Birds with New Wonder Nature Tech Product Announcement

Catch up on the latest CES 2025 announcements.

Helping Journalists Stay Up to Date on Industry News

These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists.

Once they’re signed up, reporters, bloggers, and freelancers have access to the following free features:

Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more.Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger’s next story.Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles.Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more.

About PR Newswire

PR Newswire is the industry’s leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

For questions, contact the team at media.relations@cision.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/16-press-releases-you-need-to-see-this-week-302347612.html

SOURCE PR Newswire

Continue Reading

Technology

Inspira™ Preparing Production in Response to Spread of Respiratory Virus in China

Published

on

By

RA’ANANA, Israel, Jan. 10, 2025 /PRNewswire/ — Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (“Inspira” or the “Company”), a leader in life-support technology innovation, announced today that it is preparing for a potential production ramp-up of its INSPIRA™ ART100 device. This strategic readiness comes in light of the recent outbreak of human metapneumovirus (hMPV) in China, which has highlighted the growing need for advanced respiratory care technologies globally.

Inspira is already in discussions with leading providers in affected regions to evaluate demand for advance respiratory solutions and deployment of the INSPIRA™ ART100 device, ensuring rapid response capabilities in case of increased demand.

As global health authorities monitor the hMPV outbreak, Inspira™ believes that it is well-positioned to meet potential increased demand for advanced respiratory support systems. Inspira is working closely with suppliers to secure necessary raw materials and components to meet potential demand spikes. The Company is following the hMPV situation globally and working to adjust production plans as needed.

“While hMPV is not a new virus, and experts indicate the current outbreak is part of normal seasonal patterns, Inspira believes in being prepared,” said Dagi Ben-Noon, CEO of Inspira. “Our increased production capacity will help ensure healthcare providers have access to vital respiratory care equipment should the need arise.”

Inspira emphasizes that its preparedness measures are precautionary and align with the Company’s commitment to global health readiness. The Company will work closely with health authorities in affected regions and adjust its plans based on the evolving situation.

Inspira™ Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical technology company in the life support and respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA™ ART), a groundbreaking device poised to revolutionize the $19 billion mechanical ventilation market. With 20 million intensive care unit patients with acute respiratory failure each year, many of whom rely on mechanical ventilators, the INSPIRA ART offers a potential alternative by elevating and stabilizing decreasing oxygen saturation levels in minutes without a ventilator, with patients being awake during treatment. The INSPIRA ART is being equipped with a clip-on HYLA™ blood sensor, a real-time continuous blood monitoring technology, aiming to alert physicians of changes in a patient’s condition without the need for intermittent actual blood samples, aiming to support physicians in making informed decisions.

In June and July 2024, respectively, the Company’s INSPIRA™ ART100 system has obtained FDA 510(k) clearance for use in CBP procedures, along with the Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.

The Company’s other products and technologies, including the INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the INSPIRA™ Cardi-ART portable modular device, VORTX™ Oxygen Delivery System, and HYLA™ blood sensor, are currently being designed and developed, and have not yet been tested or used in humans nor approved by any regulatory entity.

For more information, please visit our corporate website at https://inspira-technologies.com

Forward-Looking Statement Disclaimer This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the growing need for advanced respiratory care technologies and its ability to adjust its plans to rapidly respond in case of increased demand. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website at www.sec.gov.

Contact: Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485

MRK-ARS-113

Copyright © 2018-2025 Inspira Technologies OXY B.H.N. LTD., All rights reserved.

Logo: https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/inspira-preparing-production-in-response-to-spread-of-respiratory-virus-in-china-302347881.html

SOURCE Inspira Technologies

Continue Reading

Trending